SA News • Wed, Sep. 3
There are no Transcripts on RGRX.
Wed, Sep. 3, 5:17 PM
- RegeneRx Biopharmaceuticals (OTCQB:RGRX +17.1%) receives the final payment of $1M of the $2.5M product license and securities purchase agreement with G-treeBNT Co., Ltd. Proceeds have been dedicated to the development of the RegeneRx's RGN-259, a preservative-free eye drop product for certain Asian markets.
- G-treeBNT purchased 8,333,333 shares of RGRX common stock at $0.12 per share and retains an option to purchase an additional shares for $825K at $0.15 per share until January 31, 2015.
Sep. 29, 2009, 12:05 PM
There are no StockTalks on this stock yet.
RGRX vs. ETF Alternatives
RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.
Other News & PR